1
|
Hashad RA, Singla R, Bhangu SK, Jap E, Zhu H, Peleg AY, Blakeway L, Hagemeyer CE, Cavalieri F, Ashokkumar M, Alt K. Corrigendum to "Chemoenzymatic surface decoration of Nisin-shelled nanoemulsions: Novel targeted drug-nanocarriers for cancer applications" [Ultrason. Sonochem. 90 (2022) 106183]. Ultrason Sonochem 2024; 105:106862. [PMID: 38580569 PMCID: PMC11059118 DOI: 10.1016/j.ultsonch.2024.106862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/07/2024]
Affiliation(s)
- Rania A Hashad
- NanoTheranostics Laboratory, Australian Center for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
| | - Ritu Singla
- School of Chemistry, University of Melbourne, VIC 3010, Australia
| | | | - Edwina Jap
- NanoTheranostics Laboratory, Australian Center for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia
| | - Haiyan Zhu
- School of Chemistry, University of Melbourne, VIC 3010, Australia; School of Science, RMIT University, Melbourne, Victoria 3000, Australia
| | - Anton Y Peleg
- Department of Infectious Diseases, The Alfred Hospital & Monash University, Vic 3004, Australia
| | - Luke Blakeway
- Department of Infectious Diseases, The Alfred Hospital & Monash University, Vic 3004, Australia
| | - Christoph E Hagemeyer
- NanoBiotechnology Laboratory, Australian Center for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia
| | | | | | - Karen Alt
- NanoTheranostics Laboratory, Australian Center for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia.
| |
Collapse
|
2
|
Hashad RA, Jap E, Casey JL, Candace Ho YT, Wright A, Thalmann C, Sleeman M, Lupton DW, Hagemeyer CE, Cryle MJ, Robert R, Alt K. Chemoselective Methionine Labelling of Recombinant Trastuzumab Shows High In Vitro and In Vivo Tumour Targeting. Chemistry 2023; 29:e202202491. [PMID: 36451579 PMCID: PMC10946977 DOI: 10.1002/chem.202202491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Revised: 11/28/2022] [Accepted: 11/29/2022] [Indexed: 12/03/2022]
Abstract
A highly effective 2-step system for site-specific antibody modification and conjugation of the monoclonal antibody Herceptin (commercially available under Trastuzumab) in a cysteine-independent manner was used to generate labelled antibodies for in vivo imaging. The first step contains redox-activated chemical tagging (ReACT) of thioethers via engineered methionine residues to introduce specific alkyne moieties, thereby offering a novel easy way to fundamentally change the process of antibody bioconjugation. The second step involves modification of the introduced alkyne via azide-alkyne cycloaddition 'click' conjugation. The versatility of this 2-step approach is demonstrated here by the selective incorporation of a fluorescent dye but can also be applied to a wide variety of different conjugation partners depending on the desired application in a facile manner. Methionine-modified antibodies were characterised in vitro, and the diagnostic potential of the most promising variant was further analysed in an in vivo xenograft animal model using a fluorescence imaging modality. This study demonstrates how methionine-mediated antibody conjugation offers an orthogonal and versatile route to the generation of tailored antibody conjugates with in vivo applicability.
Collapse
Affiliation(s)
- Rania A. Hashad
- Australian Centre for Blood DiseasesCentral Clinical SchoolMonash UniversityMelbourneVictoria3004Australia
- Department of Pharmaceutics and Industrial PharmacyFaculty of PharmacyAin Shams University1181CairoEgypt
| | - Edwina Jap
- Australian Centre for Blood DiseasesCentral Clinical SchoolMonash UniversityMelbourneVictoria3004Australia
| | - Joanne L. Casey
- Department of PhysiologyBiomedicine Discovery InstituteMonash UniversityClaytonVictoria3800Australia
| | - Y. T. Candace Ho
- Department of Biochemistry and Molecular BiologyBiomedicine Discovery InstituteMonash UniversityClaytonVictoria 3800 (Australia)EMBL AustraliaMonash UniversityClaytonVictoria3800Australia
- ARC Centre of Excellence for Innovations in Peptide and Protein ScienceMonash UniversityClayton3800VictoriaAustralia
| | - Alexander Wright
- School of ChemistryMonash UniversityClayton3800VictoriaAustralia
| | - Claudia Thalmann
- Department of PhysiologyBiomedicine Discovery InstituteMonash UniversityClaytonVictoria3800Australia
| | - Mark Sleeman
- Department of PhysiologyBiomedicine Discovery InstituteMonash UniversityClaytonVictoria3800Australia
| | - David W. Lupton
- School of ChemistryMonash UniversityClayton3800VictoriaAustralia
| | - Christoph E. Hagemeyer
- Australian Centre for Blood DiseasesCentral Clinical SchoolMonash UniversityMelbourneVictoria3004Australia
| | - Max J. Cryle
- Department of Biochemistry and Molecular BiologyBiomedicine Discovery InstituteMonash UniversityClaytonVictoria 3800 (Australia)EMBL AustraliaMonash UniversityClaytonVictoria3800Australia
- ARC Centre of Excellence for Innovations in Peptide and Protein ScienceMonash UniversityClayton3800VictoriaAustralia
| | - Remy Robert
- Department of PhysiologyBiomedicine Discovery InstituteMonash UniversityClaytonVictoria3800Australia
| | - Karen Alt
- Australian Centre for Blood DiseasesCentral Clinical SchoolMonash UniversityMelbourneVictoria3004Australia
| |
Collapse
|
3
|
Hashad RA, Singla R, Kaur Bhangu S, Jap E, Zhu H, Peleg AY, Blakeway L, Hagemeyer CE, Cavalieri F, Ashokkumar M, Alt K. Chemoenzymatic surface decoration of Nisin-shelled nanoemulsions: Novel targeted drug-nanocarriers for cancer applications. Ultrason Sonochem 2022; 90:106183. [PMID: 36201933 PMCID: PMC9554623 DOI: 10.1016/j.ultsonch.2022.106183] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 08/04/2022] [Accepted: 08/05/2022] [Indexed: 06/16/2023]
Abstract
Nisin, a peptide used as a natural food preservative, is employed in this work for the development of a novel nanocarrier system. Stable and uniform nisin-shelled nanoemulsions (NSNE) with a diameter of 100 ± 20 nm were successfully prepared using 20 kHz flow-through ultrasonication technique. The NSNE showed limited toxicity, high bactericidal activity and high drug loading capacity (EE 65 % w/w). In addition, the nisin shell was exploited for the site-specific attachment of a recombinantly produced cancer targeting ligand (αHER2LPETG IgG). Employing a unique two phases (bio-click) approach which involved both Sortase A mediated Azide Bioconjugation (SMAB) and Strain Promoted Azide Alkyne Cycloaddition (SPAAC) reactions, targeted NSNE (NSNEDOX-αHER2 IgG) were successfully assembled and loaded with the chemotherapeutic drug Doxorubicin (DOX). Finally, NSNEDOX-αHER2 IgG showed cancer-specific binding and augmented cytotoxicity to HER2 expressing tumour cells.
Collapse
Affiliation(s)
- Rania A Hashad
- NanoTheranostics Laboratory, Australian Center for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia; NanoBiotechnology Laboratory, Australian Center for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, AinShamsUniversity, Cairo, Egypt
| | - Ritu Singla
- School of Chemistry, University of Melbourne, VIC 3010, Australia
| | | | - Edwina Jap
- NanoTheranostics Laboratory, Australian Center for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia
| | - Haiyan Zhu
- School of Chemistry, University of Melbourne, VIC 3010, Australia; School of Science, RMIT University, Melbourne, VIC 3000, Australia
| | - Anton Y Peleg
- Department of Infectious Diseases, The Alfred Hospital & Monash University, VIC 3004, Australia
| | - Luke Blakeway
- Department of Infectious Diseases, The Alfred Hospital & Monash University, VIC 3004, Australia
| | - Christoph E Hagemeyer
- NanoBiotechnology Laboratory, Australian Center for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia
| | | | | | - Karen Alt
- NanoTheranostics Laboratory, Australian Center for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia.
| |
Collapse
|
4
|
Alt K, Carraro F, Jap E, Linares-Moreau M, Riccò R, Righetto M, Bogar M, Amenitsch H, Hashad RA, Doonan C, Hagemeyer CE, Falcaro P. Self-Assembly of Oriented Antibody-Decorated Metal-Organic Framework Nanocrystals for Active-Targeting Applications. Adv Mater 2022; 34:e2106607. [PMID: 34866253 DOI: 10.1002/adma.202106607] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/22/2021] [Revised: 10/27/2021] [Indexed: 06/13/2023]
Abstract
Antibody (Ab)-targeted nanoparticles are becoming increasingly important for precision medicine. By controlling the Ab orientation, targeting properties can be enhanced; however, to afford such an ordered configuration, cumbersome chemical functionalization protocols are usually required. This aspect limits the progress of Abs-nanoparticles toward nanomedicine translation. Herein, a novel one-step synthesis of oriented monoclonal Ab-decorated metal-organic framework (MOF) nanocrystals is presented. The crystallization of a zinc-based MOF, Zn2 (mIM)2 (CO3 ), from a solution of Zn2+ and 2-methylimidazole (mIM), is triggered by the fragment crystallizable (Fc) region of the Ab. This selective growth yields biocomposites with oriented Abs on the MOF nanocrystals (MOF*Ab): the Fc regions are partially inserted within the MOF surface and the antibody-binding regions protrude from the MOF surface toward the target. This ordered configuration imparts antibody-antigen recognition properties to the biocomposite and shows preserved target binding when compared to the parental antibodies. Next, the biosensing performance of the system is tested by loading MOF*Ab with luminescent quantum dots (QD). The targeting efficiency of the QD-containing MOF*Ab is again, fully preserved. The present work represents a simple self-assembly approach for the fabrication of antibody-decorated MOF nanocrystals with broad potential for sensing, diagnostic imaging, and targeted drug delivery.
Collapse
Affiliation(s)
- Karen Alt
- Central Clinical School, Australian Centre of Blood Disease, Monash University, Melbourne, Victoria, 3004, Australia
| | - Francesco Carraro
- Institute of Physical and Theoretical Chemistry, Graz University of Technology, Graz, 8010, Austria
| | - Edwina Jap
- Central Clinical School, Australian Centre of Blood Disease, Monash University, Melbourne, Victoria, 3004, Australia
| | - Mercedes Linares-Moreau
- Institute of Physical and Theoretical Chemistry, Graz University of Technology, Graz, 8010, Austria
| | - Raffaele Riccò
- Institute of Physical and Theoretical Chemistry, Graz University of Technology, Graz, 8010, Austria
- Department of Industrial Systems Engineering, School of Engineering and Technology, Asian Institute of Technology (AIT), PO Box 4, Klong Luang, Pathum Thani, 12120, Thailand
| | - Marcello Righetto
- Division of Physics and Applied Physics, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore, 637371, Singapore
| | - Marco Bogar
- Institute of Inorganic Chemistry, Graz University of Technology, Graz, 8010, Austria
| | - Heinz Amenitsch
- Institute of Inorganic Chemistry, Graz University of Technology, Graz, 8010, Austria
| | - Rania A Hashad
- Central Clinical School, Australian Centre of Blood Disease, Monash University, Melbourne, Victoria, 3004, Australia
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt
| | - Christian Doonan
- School of Physical Sciences, Faculty of Sciences, University of Adelaide, Adelaide, South Australia, 5005, Australia
| | - Christoph E Hagemeyer
- Central Clinical School, Australian Centre of Blood Disease, Monash University, Melbourne, Victoria, 3004, Australia
| | - Paolo Falcaro
- Institute of Physical and Theoretical Chemistry, Graz University of Technology, Graz, 8010, Austria
| |
Collapse
|
5
|
Abstract
The current advances in nanoengineered materials coupled with the precise targeting capability of recombinant antibodies can create nanoscale diagnostics and therapeutics which show enhanced accumulation and extended retention at a target tissue. Smaller antibodies such as single-chain variable fragments (scFv) preserve the selective and strong binding of their parent antibody to their antigen with the benefits of low immunogenicity, more efficient tissue penetration and easy introduction of functional residues suitable for site-specific conjugation. This is of high importance as nonspecific antibody modification often involves attachment to free cysteine or lysine amino acids which may reside in the active site, leading to reduced antigen binding.In this chapter, we outline a facile and versatile chemoenzymatic approach for production of targeted nanocarrier scFv conjugates using the bacterial trans-peptidase Sortase A (Srt A). Srt A efficiently mediates sequence-specific peptide ligation under mild conditions and has few undesirable side reactions. We first describe the production, purification and characterization of Srt A enzyme and a scFv construct which targets activated platelets, called scFvanti-GPIIb/IIIa. Following this, our protocol illustrates the chemoenzymatic modification of the antibody at the C-terminus with an orthogonal click chemistry linker. This avoids any random attachment to the biologically active antigen binding site of the antibody. Finally, we describe the modification of a nanoparticle surface with scFv attachment via two methods: (1) direct Sortase-mediated conjugation; or (2) a two-step system which consists of scFv Sortase-mediated conjugation followed by strain promoted azide-alkyne cycloaddition. Finally, methodology is described to assess the successful assembly of targeted particles.
Collapse
Affiliation(s)
- Rania A Hashad
- NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia
| | - Jaclyn L Lange
- NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia
| | - Natasha C W Tan
- NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia
| | - Karen Alt
- NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia.
| | - Christoph E Hagemeyer
- NanoBiotechnology Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia.
| |
Collapse
|
6
|
Hashad RA, Ishak RA, Geneidi AS, Mansour S. Methotrexate loading in chitosan nanoparticles at a novel pH: Response surface modeling, optimization and characterization. Int J Biol Macromol 2016; 91:630-9. [DOI: 10.1016/j.ijbiomac.2016.06.014] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2016] [Revised: 05/15/2016] [Accepted: 06/06/2016] [Indexed: 02/02/2023]
|
7
|
Hashad RA, Ishak RA, Fahmy S, Mansour S, Geneidi AS. Chitosan-tripolyphosphate nanoparticles: Optimization of formulation parameters for improving process yield at a novel pH using artificial neural networks. Int J Biol Macromol 2016; 86:50-8. [DOI: 10.1016/j.ijbiomac.2016.01.042] [Citation(s) in RCA: 73] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Revised: 01/10/2016] [Accepted: 01/11/2016] [Indexed: 01/05/2023]
|
8
|
Hashad RA, Hamed NA, El Gharabawy MM, El Metwally HA, Morsi MG. Interleukins 12 and 13 levels among beta-thalassaemia major patients. East Mediterr Health J 2013; 19:181-185. [PMID: 23516830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The role of inflammatory cytokines in the pathophysiology of beta-thalassaemia is still unclear. In this study production levels of interleukins (IL)-12 and IL-13 were measured by commercial ELISA in culture supernatants of mitogen-stimulated peripheral blood mononuclear cells-from 30 non-splenectomized beta-thalassaemia cases with iron overload and 20 age- and sex-matched healthy individuals. IL-12 levels were significantly lower among cases compared with controls (91.4 pg/mL versus 154.6 pg/mL), while IL-13 levels were significantly higher (42.5 pg/mL versus 5.7 pg/mL). There was a significant negative correlation between IL-12 and lL-13 levels among beta-thalassaemia cases (r= -0.42). Patients with beta-thalassaemia alone had higher IL-12 levels than beta-thalassaemia patients who were seropositive for chronic hepatitis B or C virus infection (140 pg/mL versus 50 pg/mL); IL-13 levels were slightly lower (65 pg/mL versus 67 pg/mL). An imbalance in the IL-12/IL-13 axis may be relevant to the pathophysiology of beta-thalassaemia.
Collapse
Affiliation(s)
- R A Hashad
- Department of Medical Microbiology and Immunology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt
| | | | | | | | | |
Collapse
|